0000000000235880

AUTHOR

Marzia Lazzari

showing 2 related works from this author

Preventing and managing herpes zoster: key actions to foster healthy aging

2015

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can prot…

Gerontologymedicine.medical_specialtyPopulation ageingAgingSettore MED/17 - Malattie InfettiveImmunosenescenceCost-Benefit AnalysisHerpes zosterAlternative medicinePsychological interventionSocio-culturaleDiseaseSettore MED/42 - Igiene Generale E ApplicataQuality of life (healthcare)medicineHerpes Zoster VaccineHumansHerpes zoster; Immunosenescence; Vaccine; Aged; Cost-Benefit Analysis; Herpes Zoster; Herpes Zoster Vaccine; Humans; Italy; Middle Aged; Quality of Life; Aging; Vaccination; Aging; Geriatrics and GerontologyAgedbusiness.industryTetanusVaccinationHerpes zoster; Immunosenescence; Vaccine; Aging; Geriatrics and GerontologyMiddle Agedmedicine.diseaseComorbidityVaccinationItalyQuality of LifeGeriatrics and GerontologybusinessVaccineVaccine; Herpes zoster;Immunosenescence
researchProduct

Reducing the burden of Herpes Zoster in Italy.

2015

Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ is Post-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6 months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinical studies sh…

medicine.medical_specialtyPediatricsHerpes Zoster epidemiology burden prevention immunizationSettore MED/17 - Malattie InfettiveCost-Benefit AnalysisImmunologyNeuralgia PostherpeticDiseaseSettore MED/42 - Igiene Generale E ApplicataimmunizationHerpes ZosterHerpes Zoster; epidemiology; burden; prevention; immunizationburdenChickenpox VaccinepreventionEpidemiologymedicineHumansImmunology and AllergyChickenpox VaccinePharmacologyHerpes Zoster; burden; epidemiology; immunization; preventionbusiness.industryIncidenceIncidence (epidemiology)medicine.diseaseSurgeryVaccinationAllodyniaItalyNeuralgiaepidemiologyViral diseasemedicine.symptombusinessResearch Paper
researchProduct